Trial Profile

A phase I study of the combination of daily oral pazopanib with intravenous ifosfamide in patients with advanced solid malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifosfamide (Primary) ; Pazopanib (Primary)
Indications Solid tumours
Focus Adverse reactions; Biomarker
Acronyms Pazi

Most Recent Events

01 Jan 2025 Results (n=49) from two different studies The patients investigated were drawn from two studies on IFO with coadministration of pazopanib or sunitinib conducted in Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, assessing peripheral and central neurotoxicity, caused by this drug combination published in the Biomedicine and Pharmacotherapy
16 Nov 2015 Status changed from recruiting to completed.
06 Nov 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com